Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: DDD Clear all
Completed Phase 2 Interventional Results available

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

NCT03369236
View directory record Official record
Conditions
C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
Danicopan, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
17 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 10, 2026, 1:21 PM EDT
Not listed No phase listed Observational

The PerX360º System™ Registry

NCT01796535
View directory record Official record
Conditions
DDD
Interventions
Not listed
Lead sponsor
Interventional Spine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Saint Augustine, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Sep 10, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05067127
View directory record Official record
Conditions
C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions
Pegcetacoplan, Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Terminated No phase listed Observational

PMCF Study to Evaluate the VERTICALE® Cervical System in Spine Surgery According to Its Intended Use.

NCT05489822
View directory record Official record
Conditions
Degenerative Disc Disease (DDD), Instabilities, Trauma, Deformity
Interventions
VERTICALE® Cervical System
Device
Lead sponsor
Silony Medical GmbH
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

NCT04572854
View directory record Official record
Conditions
C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

NCT00071058
View directory record Official record
Conditions
Adrenal Cortex Neoplasms
Interventions
XR9576 (Tariquidar)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Sep 10, 2026, 1:21 PM EDT
Terminated Not applicable Interventional

Kineflex|C Artificial Disc System to Treat Cervical Degenerative Disc Disease (DDD)

NCT00374413
View directory record Official record
Conditions
Degenerative Disc Disease (DDD)
Interventions
Artificial disk, Artificial disc
Device
Lead sponsor
SpinalMotion
Industry
Eligibility
18 Years to 60 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
21
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 10, 2026, 1:21 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease

NCT07254806
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
IDCT (rebonuputemcel), Sham (No Treatment)
Biological · Other
Lead sponsor
DiscGenics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Recruiting Phase 3 Interventional

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

NCT03583710
View directory record Official record
Conditions
ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma
Interventions
Cisplatin, Etoposide, Mitotane, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Not listed No phase listed Observational

Retrospective, Multicenter Clinical Evaluation of Health Economic Drivers and Complications for Two Lumbar Fusion Procedures

NCT02171169
View directory record Official record
Conditions
Spinal Stenosis, Spondylolisthesis, Degenerative Disc Disease (DDD)
Interventions
Not listed
Lead sponsor
Baxano Surgical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Fullerton, California • Waterford, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 10, 2026, 1:21 PM EDT
Recruiting Not applicable Interventional

Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices

NCT06937658
View directory record Official record
Conditions
Pacemaker DDD, Implantable Defibrillator User
Interventions
Alert-based care, Guideline-based care
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Recruiting Not applicable Interventional

Biologic Injection For Adults With Lumbar Disc Herniation

NCT07386548
View directory record Official record
Conditions
Degenerative Disc Disease, DDD, Degenerative Disc Disease Lumbar, Degenerative Disc Disease, Lumbar, Lumbar Disc Herniation, Disc Herniation, Lumbar, Bone Marrow Aspirate Concentrate, Intervertebral Disc Displacement, Low Back Pain, Chronic Low Back Pain (CLBP), CLBP - Chronic Low Back Pain
Interventions
Bone Marrow Aspirate Concentrate (BMAC)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Recruiting Not applicable Interventional

HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs

NCT06011551
View directory record Official record
Conditions
Degenerative Disc Disease (DDD)
Interventions
The ReGelTec HYDRAFIL™ System, Conservative Care Management
Device · Other
Lead sponsor
ReGelTec, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Terminated Phase 1 Interventional

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

NCT01791686
View directory record Official record
Conditions
Dense Deposit Disease, Membranoproliferative Glomerulonephritis Type II, C3 Glomerulonephritis
Interventions
CDX-1135
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 10, 2026, 1:21 PM EDT
Not yet recruiting Not applicable Interventional

Evaluation of the Safety and Effectiveness of the CORUS™ Posterior Cervical Stabilization System 3D (PCSS 3D) for the Treatment of 2-level Cervical Degenerative Disease

NCT07721493
View directory record Official record
Conditions
Degenerative Disc Disease(DDD)
Interventions
Circumferential Cervical Fusion (CCF), Anterior Cervical Discectomy and Fusion
Device · Procedure
Lead sponsor
Providence Medical Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Terminated Not applicable Interventional Results available

Clinical Outcomes of Lumbar Degenerative Disc Disease in Active-Duty U.S. Service Personnel

NCT01028300
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
ProDisc™-L Total Disc Replacement (TDR)
Device
Lead sponsor
Synthes USA HQ, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 10, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

TRIUMPH Lumbar Artificial Disc IDE: A Pilot Study

NCT01198470
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
TRIUMPH® Lumbar Artificial Disc
Device
Lead sponsor
Globus Medical Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 10, 2026, 1:21 PM EDT
Not listed No phase listed Observational

InterFuse® S and T for the Treatment of Scoliosis, Spondylolisthesis and Degenerative Disc Disease (DDD)

NCT02659722
View directory record Official record
Conditions
Scoliosis, Back Pain
Interventions
InterFuse
Device
Lead sponsor
Vertebral Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 10, 2026, 1:21 PM EDT
Active, not recruiting Phase 3 Interventional

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531
View directory record Official record
Conditions
C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Gainsville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Terminated Phase 2 Interventional Results available

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

NCT00778817
View directory record Official record
Conditions
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
Interventions
IMC-A12, mitotane
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Decatur, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 10, 2026, 1:21 PM EDT
Completed No phase listed Observational

Patient Outcomes Evaluation of the EBI Vuelock™ Anterior Cervical Plate System

NCT00726128
View directory record Official record
Conditions
Trauma, Tumor, Pseudarthrosis, Scoliosis, Degenerative Disc Disease
Interventions
VueLock™ Anterior Cervical Plate
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
Not listed
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • Avon, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 10, 2026, 1:21 PM EDT
Completed Phase 3 Interventional

XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)

NCT00927238
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
XL TDR, Lumbar fusion surgery
Device · Other
Lead sponsor
NuVasive
Industry
Eligibility
18 Years to 70 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Campbell, California • Thousand Oaks, California • Durango, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Sep 10, 2026, 1:21 PM EDT
Enrolling by invitation No phase listed Observational

INDUCE: A Prospective 2-Year Spine Registry

NCT06971835
View directory record Official record
Conditions
Subjects Treated With NMP as Part of Their Spine Surgery, Degenerative Disc Disease (DDD)
Interventions
NMP
Device
Lead sponsor
Red Rock Regeneration Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 10, 2026, 1:21 PM EDT
Active, not recruiting Not applicable Interventional

The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery

NCT05740176
View directory record Official record
Conditions
Cervical Degenerative Disc Disease
Interventions
Anterior Cervical Discectomy and Fusion
Device
Lead sponsor
Synergy Spine Solutions
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
23
States / cities
Scottsdale, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 1:21 PM EDT